Literature DB >> 17598150

Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.

Yuji Nagai1, Shigeru Obayashi, Kiyoshi Ando, Motoki Inaji, Jun Maeda, Takashi Okauchi, Hiroshi Ito, Tetsuya Suhara.   

Abstract

Positron emission tomography (PET) is a useful technique for the consecutive investigation of the relationship between changes in neurotransmission biomarkers and behavioral signs in animal models of Parkinson's disease (PD). In this study, we aimed to investigate the threshold of dopamine (DA) neuron damage for the appearance of tremor by observing the longitudinal changes of pre- and post-synaptic DA biomarkers in awake monkeys using PET with multiple tracers. Three cynomolgus monkeys were treated with MPTP every 3-6 weeks until tremor was observed. Brain uptake of [11C]PE2I, [beta-11C]DOPA, and [11C]raclopride for DA transporter (DAT), DOPA utilization, and DA D2 receptor were measured using PET as a single set in awake condition. Sets of PET scans were repeated in parallel with continuous behavioral estimation. The pre-synaptic biomarkers of DA neuron in the striatum decreased [11C]PE2I binding and [beta-11C]DOPA uptake in an MPTP dose-dependent manner. Tremor was not observed until striatal [11C]PE2I binding was reduced to about 15% of the pretreatment level and [beta-11C]DOPA uptake was reduced to about 34%. DA D2 receptor measured by [11C]raclopride was not significantly changed throughout the experiment. Our results revealed that it is possible to quantitatively define the threshold of the onset of behavioral PD signs by monitoring spontaneous motor activity, and in vivo PET with DAT marker can be a biomarker for early diagnosis at the presymptomatic stage of PD and for high-risk groups. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598150     DOI: 10.1002/syn.20431

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  7 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.

Authors:  Gunasingh Masilamoni; John Votaw; Leonard Howell; Rosa M Villalba; Mark Goodman; Ronald J Voll; Jeffrey Stehouwer; Thomas Wichmann; Yoland Smith
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

Review 3.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

4.  Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.

Authors:  R Pattarini; Y Rong; K R Shepherd; Y Jiao; C Qu; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2012-04-24       Impact factor: 3.590

5.  Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.

Authors:  Kiyoshi Ando; Jun Maeda; Motoki Inaji; Takashi Okauchi; Shigeru Obayashi; Makoto Higuchi; Tetsuya Suhara; Yoshikuni Tanioka
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

6.  PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.

Authors:  Kiyoshi Ando; Shigeru Obayashi; Yuji Nagai; Arata Oh-Nishi; Takafumi Minamimoto; Makoto Higuchi; Takashi Inoue; Toshio Itoh; Tetsuya Suhara
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

7.  Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.

Authors:  Kiyoshi Ando; Chiyoko Nishime; Ryo Inoue; Eiko Nishinaka; Kenji Kawai; Koji Urano; Hideki Tsutsumi
Journal:  Behav Pharmacol       Date:  2017-12       Impact factor: 2.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.